Tox21

Tox21
Name	Tox21
Established	2007
Focus	High-throughput toxicology, chemical safety
Participants	National Institutes of Health; Environmental Protection Agency; Food and Drug Administration; National Center for Advancing Translational Sciences

Tox21

Tox21 is a multi-agency US research consortium created to develop and apply high-throughput screening strategies for evaluating chemical hazards and biological responses. It aims to shift toxicity testing from traditional William Harvey-era animal models toward mechanistic, in vitro, and computational approaches informed by projects such as Human Genome Project, ENCODE Project, and initiatives like NIH Roadmap for Medical Research. The program sits at the intersection of regulatory science represented by the United States Environmental Protection Agency and biomedical research institutions exemplified by the National Institutes of Health and Food and Drug Administration.

Background and objectives

Tox21 originated amid debates involving stakeholders such as advocates from National Research Council (United States), policymakers in the United States Congress, and scientists associated with National Academy of Sciences (United States), who called for modernizing toxicity testing after reports like the Toxicity Testing in the 21st Century report. Its primary objectives include prioritizing chemicals for further testing in contexts like the Frank R. Lautenberg Chemical Safety for the 21st Century Act, reducing reliance on animal studies referenced by groups such as PETA and Physicians Committee for Responsible Medicine, and developing predictive models paralleling efforts from the Cancer Genome Atlas. The program aligns with translational aims of the National Center for Advancing Translational Sciences and regulatory endpoints used by the European Chemicals Agency and Organisation for Economic Co-operation and Development.

Organization and partners

Tox21 is a partnership among federal agencies and research entities including the National Toxicology Program, the National Institute of Environmental Health Sciences, the Environmental Protection Agency, the Food and Drug Administration, and the National Institutes of Health. Collaborative networks span academic centers such as Harvard University, Massachusetts Institute of Technology, University of California, Berkeley, and industrial and non-profit stakeholders like the Chemical Industry Institute of Toxicology and American Chemical Society. International collaborations have engaged organizations like the European Union, World Health Organization, and the Organisation for Economic Co-operation and Development to harmonize assay standards and data sharing initiatives pioneered in consortia such as ENCODE Project and Human Cell Atlas.

Methodologies and assays

The program employs high-throughput screening (HTS) and high-content screening (HCS) platforms drawing on technologies developed by companies and labs tied to Broad Institute, Thermo Fisher Scientific, and PerkinElmer. Assay modalities include reporter gene assays influenced by techniques used in Green Fluorescent Protein studies, receptor-binding assays connected to knowledge from work on Nuclear receptor subfamily 1, group I, member 2, and pathway-based assays reflecting insights from the MAPK signaling pathway literature. Tox21 leverages automated liquid handling systems from vendors associated with the Bell Labs tradition, multiplexed readouts reminiscent of Luminex platforms, and transcriptomic profiling methods similar to those used in RNA-Seq projects. Computational toxicology methods used echo algorithms from Ensemble learning, Random forest (classification algorithm), and machine-learning efforts like DeepMind-adjacent research.

Data generation and management

Data production follows large-scale screening campaigns analogous to data models in the Human Genome Project and repositories inspired by Gene Expression Omnibus and European Nucleotide Archive. Chemical libraries include legacy libraries from programs such as ToxCast and curated sets comparable to collections at PubChem, ChEMBL, and ZINC (database). Data stewardship practices draw on standards advanced by FAIR data principles advocates and infrastructure methods used in National Center for Biotechnology Information. Integration efforts coordinate metadata vocabularies resembling work by the Open Biological and Biomedical Ontology community and curation pipelines parallel to those at the Protein Data Bank. Data access policies intersect with deliberations by Freedom of Information Act stakeholders and standards discussed in forums like the Global Alliance for Genomics and Health.

Key findings and impact

Tox21 has generated large datasets that identified mechanistic signatures for perturbations in pathways connected to actors such as Aryl hydrocarbon receptor, Peroxisome proliferator-activated receptor, and Estrogen receptor alpha. These outputs informed risk-prioritization frameworks employed by the Environmental Protection Agency and contributed to alternative testing strategies cited in regulatory reviews by the Food and Drug Administration. The program's influence is visible in academic outputs published by groups at Johns Hopkins University, Stanford University, and University of Cambridge, and in translational applications linked to pharmaceutical safety programs at Pfizer and GlaxoSmithKline. Cross-disciplinary citations evoke methods from the Systems Biology community and modeling paradigms from Physiologically Based Pharmacokinetic modeling efforts.

Challenges and criticisms

Critiques mirror debates encountered in reviews by the National Research Council (United States) and concerns raised by advocacy organizations like Environmental Working Group and Center for Science in the Public Interest regarding extrapolation to human health outcomes. Technical challenges include assay interference echoing problems documented in the PAINS (Pan Assay Interference Compounds) literature, reproducibility issues discussed at forums such as AAAS meetings, and gaps in capturing complex endpoints noted in studies from European Food Safety Authority. Ethical and policy questions surfaced in debates involving the U.S. Congress and commentary from think tanks like Brookings Institution and Heritage Foundation about regulatory use of non-animal data.

Future directions and initiatives

Future plans emphasize integration with organotypic models championed by labs affiliated with Wyss Institute, expansion of single-cell assays reflecting progress at the Human Cell Atlas, and incorporation of advanced in silico frameworks akin to developments from DeepMind and OpenAI research ecosystems. Proposed extensions include linking Tox21 datasets to population-scale resources like the All of Us Research Program and harmonizing with international chemical assessment programs coordinated by the World Health Organization and Organisation for Economic Co-operation and Development. Continued collaboration with academic centers such as Yale University and University of Michigan and industry partners including Merck & Co. aims to translate mechanistic screens into actionable guidance for regulators and public health agencies like the Centers for Disease Control and Prevention.

Category:Toxicology